Literature DB >> 21653567

Alzheimer's disease: rapid and slow progression.

Craig J Thalhauser1, Natalia L Komarova.   

Abstract

The variability in the progression of Alzheimer's disease (AD) across patients has made identification of disease-delaying treatments difficult. Quantitative analysis of this variability has important implications in understanding the pathophysiology of AD and identifying disease-delaying treatments. The functional assessment staging (FAST) procedure characterizes seven stages in the course of AD from normal ageing to severe dementia. The present study applied statistical methods to analyse FAST stage durations from a dataset of 648 AD patients. These methods uncovered two distinct types of disease progression, characterized by different mean progression rates. We identified two separate distributions of FAST stage progression times differing by up to 2 years in mean duration within each stage. These results further indicate that if a patient progresses rapidly through a given FAST stage, then their further progression is also likely to be rapid. These findings support the hypothesis that progression of AD can occur via two different pathophysiological mechanisms that lead to distinct average rates of decline.

Entities:  

Mesh:

Year:  2011        PMID: 21653567      PMCID: PMC3223623          DOI: 10.1098/rsif.2011.0134

Source DB:  PubMed          Journal:  J R Soc Interface        ISSN: 1742-5662            Impact factor:   4.118


  29 in total

1.  Rapidly progressive Alzheimer's disease.

Authors:  U M Mann; E Mohr; T N Chase
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

2.  Rate of cognitive decline in AD is accelerated by the interleukin-1 alpha -889 *1 allele.

Authors:  G M Murphy; J D Claassen; J J DeVoss; N Pascoe; J Taylor; J R Tinklenberg; J A Yesavage
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

3.  Dementia: a systematic approach to identifying reversible causes.

Authors:  B Reisberg
Journal:  Geriatrics       Date:  1986-04

4.  The use of mixture models for the analysis of survival data with long-term survivors.

Authors:  V T Farewell
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

5.  Vascular disease and risk factors, rate of progression, and survival in Alzheimer's disease.

Authors:  Deepika Bhargava; Myron F Weiner; Linda S Hynan; Ramon Diaz-Arrastia; Anne M Lipton
Journal:  J Geriatr Psychiatry Neurol       Date:  2006-06       Impact factor: 2.680

6.  Mortality and temporal course of probable Alzheimer's disease: a 5-year prospective study.

Authors:  B Reisberg; S H Ferris; E H Franssen; E Shulman; I Monteiro; S G Sclan; G Steinberg; A Kluger; C Torossian; M J de Leon; E Laska
Journal:  Int Psychogeriatr       Date:  1996       Impact factor: 3.878

7.  SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.

Authors:  Carlos Cruchaga; John S K Kauwe; Kevin Mayo; Noah Spiegel; Sarah Bertelsen; Petra Nowotny; Aarti R Shah; Richard Abraham; Paul Hollingworth; Denise Harold; Michael M Owen; Julie Williams; Simon Lovestone; Elaine R Peskind; Ge Li; James B Leverenz; Douglas Galasko; John C Morris; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  PLoS Genet       Date:  2010-09-16       Impact factor: 5.917

8.  Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment.

Authors:  Linda K McEvoy; Christine Fennema-Notestine; J Cooper Roddey; Donald J Hagler; Dominic Holland; David S Karow; Christopher J Pung; James B Brewer; Anders M Dale
Journal:  Radiology       Date:  2009-02-06       Impact factor: 11.105

9.  Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease.

Authors:  S Craft; L Teri; S D Edland; W A Kukull; G Schellenberg; W C McCormick; J D Bowen; E B Larson
Journal:  Neurology       Date:  1998-07       Impact factor: 9.910

10.  Physiologic modulation of natural killer cell activity as an index of Alzheimer's disease progression.

Authors:  Paolo Prolo; Francesco Chiappelli; Alberto Angeli; Andrea Dovio; Paola Perotti; Marisa Pautasso; Maria Luisa Sartori; Laura Saba; Stefano Mussino; Thomas Fraccalini; Fausto Fantó; Cristina Mocellini; Maria Gabriella Rosso; Enzo Grasso
Journal:  Bioinformation       Date:  2007-03-21
View more
  16 in total

1.  Genetic determinants of disease progression in Alzheimer's disease.

Authors:  Xingbin Wang; Oscar L Lopez; Robert A Sweet; James T Becker; Steven T DeKosky; Mahmud M Barmada; F Yesim Demirci; M Ilyas Kamboh
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo.

Authors:  Sarah K Kaufman; David W Sanders; Talitha L Thomas; Allison J Ruchinskas; Jaime Vaquer-Alicea; Apurwa M Sharma; Timothy M Miller; Marc I Diamond
Journal:  Neuron       Date:  2016-10-27       Impact factor: 17.173

3.  Leverage Real-world Longitudinal Data in Large Clinical Research Networks for Alzheimer's Disease and Related Dementia (ADRD).

Authors:  Rui Duan; Zhaoyi Chen; Jiayi Tong; Chongliang Luo; Tianchen Lyu; Cui Tao; Demetrius Maraganore; Jiang Bian; Yong Chen
Journal:  AMIA Annu Symp Proc       Date:  2021-01-25

4.  Searching for an endogenous anti-Alzheimer molecule: identifying small molecules in the brain that slow Alzheimer disease progression by inhibition of ß-amyloid aggregation.

Authors:  Autumn R Meek; Gordon A Simms; Donald F Weaver
Journal:  J Psychiatry Neurosci       Date:  2013-07       Impact factor: 6.186

5.  First-in-Rat Study of Human Alzheimer's Disease Tau Propagation.

Authors:  Tomas Smolek; Santosh Jadhav; Veronika Brezovakova; Veronika Cubinkova; Bernadeta Valachova; Petr Novak; Norbert Zilka
Journal:  Mol Neurobiol       Date:  2018-05-16       Impact factor: 5.590

6.  The natural history of early-onset dementia: the Artemis Project.

Authors:  Emily R Atkins; Max K Bulsara; Peter K Panegyres
Journal:  BMJ Open       Date:  2012-10-10       Impact factor: 2.692

7.  Calculating stage duration statistics in multistage diseases.

Authors:  Natalia L Komarova; Craig J Thalhauser
Journal:  PLoS One       Date:  2011-12-07       Impact factor: 3.240

Review 8.  Amyloid plaques beyond Aβ: a survey of the diverse modulators of amyloid aggregation.

Authors:  Katie L Stewart; Sheena E Radford
Journal:  Biophys Rev       Date:  2017-06-19

9.  Trajectories of dementia-related cognitive decline in a large mental health records derived patient cohort.

Authors:  Elizabeth Baker; Ehtesham Iqbal; Caroline Johnston; Matthew Broadbent; Hitesh Shetty; Robert Stewart; Robert Howard; Stephen Newhouse; Mizanur Khondoker; Richard J B Dobson
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

10.  Factors determining disease duration in Alzheimer's disease: a postmortem study of 103 cases using the Kaplan-Meier estimator and Cox regression.

Authors:  R A Armstrong
Journal:  Biomed Res Int       Date:  2014-01-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.